PIVKA-II Is the Best Prognostic Predictor in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation Therapy

Publisher： Karger

E-ISSN： 1423-0232|75|1|91-98

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.1, 2008-12, pp. : 91-98

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 52-57

Karger

Access to resources Recommend Favorite

Favorable α‐fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 3, 2010-03 ,pp. : 605-612

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 132-138

Karger

Access to resources Recommend Favorite

Recent Progress in Radiofrequency Ablation Therapy for Hepatocellular Carcinoma

By  

Oncology, Vol. 87, Iss. 1, 2014-11 ,pp. : 73-77

Karger

Access to resources Recommend Favorite

What Is the Best Time to Evaluate Treatment Response after Radiofrequency Ablation of Hepatocellular Carcinoma Using Contrast-Enhanced Sonography?

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 92-97

Karger

Access to resources Recommend Favorite